Taken together, these results demonstrate an important role of GLS2 in oxidative glutamine metabolism driven by oncogenic N-Myc, suggesting targeting GLS2 may represent an effective treatment approach to neuroblastoma patients exhibiting MYCN-amplification. Here, MYCN is linked to neuroblastoma.